{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-001454","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.951892+00:00","generated_at":"2026-06-19T08:47:01.120373+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Capricor partners with Nippon Shinyaku for CAP-1002 in Japan; $12M upfront, up to $89M milestones","bullets":["Exclusive Japan commercialization and distribution agreement for CAP-1002 in Duchenne muscular dystrophy.","Capricor receives $12M upfront plus up to ~$89M in development and sales milestones.","Capricor also gets a meaningful double-digit percentage of product revenue from Japan sales.","Capricor retains marketing authorization and clinical development; Nippon Shinyaku handles distribution.","Follows a similar U.S. deal with Nippon Shinyaku signed in January 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-001454","json":"https://secwatch.observer/filing/0001558370-23-001454.json","markdown":"https://secwatch.observer/filing/0001558370-23-001454.md","text":"https://secwatch.observer/filing/0001558370-23-001454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023001454/0001558370-23-001454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023001454/capr-20230210x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T08:47:01.120373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f14ca05834bfb1a0089337a5ca1527e1d6be882","claim":"CAPRICOR THERAPEUTICS, INC. entered into Japan Agreement with Nippon Shinyaku, Co., Ltd. valued at upfront payment of $12 million and ... additional development and sales-based milestone payments of (effective 2023-02-10).","evidence_excerpt":"Capricor Therapeutics, Inc. (the “Company” or “Capricor”) entered into an Exclusive Commercialization and Distribution Agreement (the “Japan Agreement”) with Nippon Shinyaku, Co., Ltd., a Japanese corporation, (“Nippon Shinyaku”) effective February 10, 2023.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023001454/0001558370-23-001454-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Nippon Shinyaku, Co., Ltd."},{"label":"Value","value":"upfront payment of $12 million and ... additional development and sales-based milestone payments of"},{"label":"Effective","value":"2023-02-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}